LCWP
CAPR icon

Legacy Capital Wealth Partners’s Capricor Therapeutics CAPR Stock Holding History

Legacy Capital Wealth Partners’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-12,000
Closed -$86.5K – 378
2025
Q3 		$86.5K Buy
+12,000
New +$88.4K 0.02% 375

Other funds holding CAPR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Legacy Capital Wealth Partners's CAPR Position: Q4 2025 in Review

Legacy Capital Wealth Partners sold out of Capricor Therapeutics (CAPR) in Q4 2025, closing a stake of 12,000 shares — an estimated $86.5K sold.

Legacy Capital Wealth Partners first reported a position in CAPR in Q3 2025 and held it in 1 quarter. The position peaked at $86.5K in Q3 2025. 132 funds tracked by Wall St. Rank hold CAPR as of Q4 2025.

  • Legacy Capital Wealth Partners reported no remaining Capricor Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Legacy Capital Wealth Partners sold 12,000 Capricor Therapeutics shares in Q4 2025, an estimated $86.5K.
  • Legacy Capital Wealth Partners first reported a position in Capricor Therapeutics in Q3 2025 and held it in 1 quarter.
  • Legacy Capital Wealth Partners's Capricor Therapeutics position peaked at $86.5K in Q3 2025.
  • 132 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q4 2025.

Based on Legacy Capital Wealth Partners's 13F filing for Q4 2025, filed 16 Jan 2026.